TransMedics Group, Inc. is offering 4.7 million shares of common stock. They anticipate that the initial public offering price will be between $15.00 and $17.00 per share. The Company has applied to list on NASDAQ under the symbol “TMDX”
TransMedic Group is expected to raise up to $86.8 million at a market capitalization of $308 million.
Morgan Stanley and J.P. Morgan act as manager and joint manager to the deal and Cowen and company and Canaccord Genuity act as co-managers to the deal.
TransMedic Group is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. TransMedic Group developed the OCS to replace a decades-old standard of care that we believe is significantly limiting access to life-saving transplant therapy for hundreds of thousands of patients worldwide. TransMedic Group innovative OCS technology replicates many aspects of the organ’s natural living and functioning environment outside of the human body.
TransMedic Group has booked a revenue of $13 million with a net loss of $23.8 million in the last 12 months.
Expected pricing date: May 2, 2019